Angiogenic Imbalance in Early Placental Dysfunction: Pro- and Anti-Angiogenic Factors, Pathophysiology, Screening and Therapeutic Horizons
International Journal of Molecular Sciences · 2026
DOI: 10.3390/ijms27208958 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Tamara Nikolic Turnic und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Faculty of Medical Sciences, University of Kragujevac, Svetozara Markovica 69, 34000 Kragujevac, Serbia. Hauptthemen laut MEDLINE: Placenta, Angiogenesis, Placenta Diseases, Angiogenesis Inducing Agents. Die Arbeit nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Placental dysfunction is a major component of several pregnancy complications, particularly preeclampsia and fetal growth restriction (FGR). These disorders could be presented with different phenotypes based on abnormal placentation and inadequate maternal vascular adaptation, which are baseline mechanisms in affected pregnancies. Defective trophoblast invasion and incomplete transformation of the maternal spiral arteries may produce a high-resistance uteroplacental circulation, resulting in placental hypo-perfusion, ischemia–reperfusion injury, oxidative stress and subsequent release of factors that affect maternal endothelial function. The aim of this review is to summarize the current understanding of pro-angiogenic and anti-angiogenic factors in early placental dysfunction, with special emphasis in their biological function and molecular roles, relationship with abnormal placentation and clinical significance during pregnancy. The development of placental dysfunction is generally understood as a multifactorial and multistep process. The literature evidence most often supports the three-step process of placenta dysfunction. The angiogenic imbalance may precede the clinical presentation of preeclampsia and may also be associated with fetal growth restriction. Among currently available biomarkers, the sFlt-1/PlGF ratio has the strongest clinical evidence for risk stratification in women with suspected preeclampsia. Nevertheless, the role of angiogenic factors in the earliest stages of placental dysfunction remains incompletely defined. The major challenge is to determine whether angiogenic abnormalities can identify clinically meaningful placental dysfunction early enough to permit effective intervention. This suggests that pro-angiogenic therapeutics could be a possible option for the treatment of pre-eclampsia, but also a more specific and sensitive predictive and diagnostic tool in modern obstetrics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Faculty of Medical Sciences, University of Kragujevac, Svetozara Markovica 69, 34000 Kragujevac, Serbia.
- N.A. Semashko Public Health and Healthcare Department, F.F. Erismann Institute of Public Health, I.M. Sechenov First Moscow State Medical University (Sechenov University), 119048 Moscow, Russia.
- Center of Excellence for Redox Balance Research in Cardiovascular and Metabolic Disorders, 34000 Kragujevac, Serbia.
Zitieren
APA
Nikolic Turnic, T., & Aksentijevic, M. (2026). Angiogenic Imbalance in Early Placental Dysfunction: Pro- and Anti-Angiogenic Factors, Pathophysiology, Screening and Therapeutic Horizons. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27208958
Vancouver
Nikolic Turnic T, Aksentijevic M. Angiogenic Imbalance in Early Placental Dysfunction: Pro- and Anti-Angiogenic Factors, Pathophysiology, Screening and Therapeutic Horizons. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27208958
BibTeX
@article{NikolicTurnic2026,
author = {Nikolic Turnic, Tamara and Aksentijevic, Marija},
title = {Angiogenic Imbalance in Early Placental Dysfunction: Pro- and Anti-Angiogenic Factors, Pathophysiology, Screening and Therapeutic Horizons},
journal = {International Journal of Molecular Sciences},
year = {2026},
doi = {10.3390/ijms27208958}
}
EUVIMED